Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
Identifieur interne : 002105 ( Main/Exploration ); précédent : 002104; suivant : 002106Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
Auteurs : Victor S. C. Fung [Australie] ; Lilie Herawati [Australie] ; Ying Wan [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-01-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Benserazide (administration & dosage), Benserazide (adverse effects), Benserazide (therapeutic use), Carbidopa, Carbidopa (administration & dosage), Carbidopa (adverse effects), Carbidopa (therapeutic use), Catechol O-Methyltransferase Inhibitors, Catechols (administration & dosage), Catechols (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Dyskinesia, Drug-Induced (etiology), Entacapone, Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (therapeutic use), Female, Gastrointestinal Diseases (chemically induced), Humans, Levodopa, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Nitriles (administration & dosage), Nitriles (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Quality of Life, Quality of life, Severity of Illness Index, Treatment, Treatment Outcome, early Parkinson's disease, entacapone, levodopa/carbidopa, nonfluctuators, quality of life.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Benserazide, Carbidopa, Catechols, Enzyme Inhibitors, Levodopa, Nitriles.
- chemical , adverse effects : Antiparkinson Agents, Benserazide, Carbidopa, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Benserazide, Carbidopa, Catechols, Enzyme Inhibitors, Levodopa, Nitriles.
- chemically induced : Gastrointestinal Diseases.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- psychology : Parkinson Disease.
- Aged, Catechol O-Methyltransferase Inhibitors, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Quality of Life, Severity of Illness Index, Treatment Outcome.
Abstract
We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. One hundred eighty‐four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ‐8. Secondary outcome measures were the UPDRS parts I–IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ‐8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P < 0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21878
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F97
- to stream Istex, to step Curation: 000F97
- to stream Istex, to step Checkpoint: 000D07
- to stream PubMed, to step Corpus: 001F93
- to stream PubMed, to step Curation: 001F93
- to stream PubMed, to step Checkpoint: 001C13
- to stream Ncbi, to step Merge: 002370
- to stream Ncbi, to step Curation: 002370
- to stream Ncbi, to step Checkpoint: 002370
- to stream Main, to step Merge: 002966
- to stream PascalFrancis, to step Corpus: 001017
- to stream PascalFrancis, to step Curation: 001D02
- to stream PascalFrancis, to step Checkpoint: 000D35
- to stream Main, to step Merge: 002E32
- to stream Main, to step Curation: 002105
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone</title><author><name sortKey="Fung, Victor S C" sort="Fung, Victor S C" uniqKey="Fung V" first="Victor S. C." last="Fung">Victor S. C. Fung</name></author><author><name sortKey="Herawati, Lilie" sort="Herawati, Lilie" uniqKey="Herawati L" first="Lilie" last="Herawati">Lilie Herawati</name></author><author><name sortKey="Wan, Ying" sort="Wan, Ying" uniqKey="Wan Y" first="Ying" last="Wan">Ying Wan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:175512CAA9FE2609C32FB6996E1F576DBB2267DA</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.21878</idno><idno type="url">https://api.istex.fr/document/175512CAA9FE2609C32FB6996E1F576DBB2267DA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F97</idno><idno type="wicri:Area/Istex/Curation">000F97</idno><idno type="wicri:Area/Istex/Checkpoint">000D07</idno><idno type="wicri:doubleKey">0885-3185:2009:Fung V:quality:of:life</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18846551</idno><idno type="wicri:Area/PubMed/Corpus">001F93</idno><idno type="wicri:Area/PubMed/Curation">001F93</idno><idno type="wicri:Area/PubMed/Checkpoint">001C13</idno><idno type="wicri:Area/Ncbi/Merge">002370</idno><idno type="wicri:Area/Ncbi/Curation">002370</idno><idno type="wicri:Area/Ncbi/Checkpoint">002370</idno><idno type="wicri:Area/Main/Merge">002966</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0094096</idno><idno type="wicri:Area/PascalFrancis/Corpus">001017</idno><idno type="wicri:Area/PascalFrancis/Curation">001D02</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D35</idno><idno type="wicri:doubleKey">0885-3185:2009:Fung V:quality:of:life</idno><idno type="wicri:Area/Main/Merge">002E32</idno><idno type="wicri:Area/Main/Curation">002105</idno><idno type="wicri:Area/Main/Exploration">002105</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone</title><author><name sortKey="Fung, Victor S C" sort="Fung, Victor S C" uniqKey="Fung V" first="Victor S. C." last="Fung">Victor S. C. Fung</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Movement Disorder Unit, Department of Neurology, Westmead Hospital</wicri:regionArea><wicri:noRegion>Westmead Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Herawati, Lilie" sort="Herawati, Lilie" uniqKey="Herawati L" first="Lilie" last="Herawati">Lilie Herawati</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Clinical Development and Medical Affairs, Novartis Pharmaceuticals</wicri:regionArea><wicri:noRegion>Novartis Pharmaceuticals</wicri:noRegion></affiliation></author><author><name sortKey="Wan, Ying" sort="Wan, Ying" uniqKey="Wan Y" first="Ying" last="Wan">Ying Wan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Development Biostatistic, Novartis Pharmaceuticals, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15">2009-01-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="25">25</biblScope><biblScope unit="page" to="31">31</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">175512CAA9FE2609C32FB6996E1F576DBB2267DA</idno><idno type="DOI">10.1002/mds.21878</idno><idno type="ArticleID">MDS21878</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benserazide (administration & dosage)</term><term>Benserazide (adverse effects)</term><term>Benserazide (therapeutic use)</term><term>Carbidopa</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (adverse effects)</term><term>Carbidopa (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechols (administration & dosage)</term><term>Catechols (therapeutic use)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Entacapone</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female</term><term>Gastrointestinal Diseases (chemically induced)</term><term>Humans</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Nitriles (administration & dosage)</term><term>Nitriles (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Quality of Life</term><term>Quality of life</term><term>Severity of Illness Index</term><term>Treatment</term><term>Treatment Outcome</term><term>early Parkinson's disease</term><term>entacapone</term><term>levodopa/carbidopa</term><term>nonfluctuators</term><term>quality of life</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Carbidopa</term><term>Catechols</term><term>Enzyme Inhibitors</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Carbidopa</term><term>Catechols</term><term>Enzyme Inhibitors</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Gastrointestinal Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Carbidopa</term><term>Entacapone</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Qualité de vie</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We aimed to investigate whether treatment with levodopa/carbidopa/entacapone when compared with levodopa/carbidopa improves quality of life in Parkinson's disease (PD) patients with no or minimal, nondisabling motor fluctuations. This is a multicenter, randomized, double‐blind study. One hundred eighty‐four patients on 3 to 4 equal doses of 100/25 to 200/50 mg levodopa/carbidopa or levodopa/benserazide, 0 to 3 hours of nondisabling OFF time over a 48 hour period and no dyskinesia were randomized to levodopa/carbidopa/entacapone or levodopa/carbidopa treatment for 12 weeks. The primary outcome measure was quality of life as assessed by the PDQ‐8. Secondary outcome measures were the UPDRS parts I–IV, and the Wearing Off Card. Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ‐8 scores compared to treatment with levodopa/carbidopa (mean difference 1.4 points, P = 0.021). Statistically significant improvements were seen predominantly in nonmotor domains (depression, personal relationships, communication, stigma, all P < 0.05; dressing P = 0.056). Patients who were randomly assigned to levodopa/carbidopa/entacapone also showed significantly greater improvement in UPDRS part II scores (P = 0.032) with UPDRS part III scores showing borderline significance. Differences in UPDRS parts I and IV and Wearing Off Card scores were not significant. Treatment with levodopa/carbidopa/entacapone results in improved quality of life compared with levodopa/carbidopa in PD patients with mild or minimal, nondisabling motor fluctuations. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Australie</li><li>États-Unis</li></country><region><li>New Jersey</li></region></list><tree><country name="Australie"><noRegion><name sortKey="Fung, Victor S C" sort="Fung, Victor S C" uniqKey="Fung V" first="Victor S. C." last="Fung">Victor S. C. Fung</name></noRegion><name sortKey="Herawati, Lilie" sort="Herawati, Lilie" uniqKey="Herawati L" first="Lilie" last="Herawati">Lilie Herawati</name></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Wan, Ying" sort="Wan, Ying" uniqKey="Wan Y" first="Ying" last="Wan">Ying Wan</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002105 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002105 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:175512CAA9FE2609C32FB6996E1F576DBB2267DA
|texte= Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone
}}
| This area was generated with Dilib version V0.6.23. |  |